GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

NCT06546384 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Adiposity
Fatty Liver
Alcohol Use Disorder

Interventions

DRUG: Semaglutide
BEHAVIORAL: Weight reduction recommendations (nutritional and exercise)

Sponsor

Insel Gruppe AG, University Hospital Bern